A Multi-center, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
Sirtsei Pharmaceuticals, Inc.
Summary
This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.
Eligibility
- Age range
- 18–65 years
- Sex
- All
- Healthy volunteers
- No
Key Inclusion Criteria: * Males and females, aged 18 to 65 years, inclusive. * Meet DSM-5 criteria for moderate to severe MDD, as confirmed by the Mini International Neuropsychiatric Interview (MINI). * In generally good physical health, in the opinion of the Investigator. * Body mass index (BMI) must be ≥ 18 and ≤ 45 kg/m2. Key Exclusion Criteria: * Female who is pregnant, breastfeeding, or less than 6 months postpartum at screen. * A history of or current DSM-5 diagnosis of MDD with psychotic features, any schizophrenia spectrum and other psychotic disorders, bipolar disorder, or personal…
Interventions
- DrugSP-624
Once daily oral administration of two capsules totaling 20 mg/day
- DrugPlacebo
Once daily oral administration of two matching placebo capsules
Locations (50)
- IMA Clinical ResearchPhoenix, Arizona
- Noble Clinical ResearchTucson, Arizona
- SanRo Clinical Research GroupBryant, Arkansas
- Clinical InnovationsBellflower, California
- Sun Valley Research CenterImperial, California
- Synergy San DiegoLemon Grove, California